Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed?
作者信息
Nicolosi Maura, Mudireddy Mythri, Gangat Naseema, Pardanani Animesh, Hanson Curtis A, Ketterling Rhett P, Tefferi Ayalew
机构信息
Departments of Internal Medicine and Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.
出版信息
Blood Cancer J. 2018 Jan 12;8(1):8. doi: 10.1038/s41408-017-0046-3.
Abstract
摘要
相似文献
1
Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed?骨髓纤维化中的正常核型：分析的中期相数量是否会影响预后完整性？
Blood Cancer J. 2018 Jan 12;8(1):8. doi: 10.1038/s41408-017-0046-3.
2
Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival.原发性骨髓纤维化中单体核型对总生存和无白血病生存均有害。
Blood. 2011 May 26;117(21):5612-5. doi: 10.1182/blood-2010-11-320002. Epub 2011 Mar 30.
3
Karyotype complements the International Prognostic Scoring System for primary myelofibrosis.核型补充了原发性骨髓纤维化的国际预后评分系统。
Eur J Haematol. 2009 Apr;82(4):255-9. doi: 10.1111/j.1600-0609.2009.01216.x. Epub 2008 Feb 10.
4
Isochromosome 17q in a case of myelofibrosis with myeloid metaplasia terminating in blastic transformation.
Cancer Genet Cytogenet. 1987 Feb;24(2):221-4. doi: 10.1016/0165-4608(87)90102-6.
5
Multiple chromosomal changes and karyotypic evolution in a patient with myelofibrosis.一名骨髓纤维化患者的多种染色体变化及核型演变
Cancer Genet Cytogenet. 1992 Jul 1;61(1):6-10. doi: 10.1016/0165-4608(92)90362-c.
6
Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients.原发性骨髓纤维化中 2 年死亡率大于 80%的预测因素：梅奥诊所对 884 例核型注释患者的研究。
Blood. 2011 Oct 27;118(17):4595-8. doi: 10.1182/blood-2011-08-371096. Epub 2011 Aug 31.
7
Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.原发性骨髓纤维化中整体无白血病生存的精细化细胞遗传学危险度分类：433 例患者的单中心研究。
Leukemia. 2011 Jan;25(1):82-8. doi: 10.1038/leu.2010.234. Epub 2010 Oct 14.
8
Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.
Blood. 1996 Aug 1;88(3):1013-8.
9
Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia.荧光原位杂交检测细胞遗传学在骨髓纤维化伴髓外化生患者中的预后相关性
Cancer. 2006 Dec 15;107(12):2801-6. doi: 10.1002/cncr.22318.
10
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.DIPSS plus：一种改良的原发性骨髓纤维化动态国际预后评分系统，纳入了核型、血小板计数和输血状态的预后信息。
J Clin Oncol. 2011 Feb 1;29(4):392-7. doi: 10.1200/JCO.2010.32.2446. Epub 2010 Dec 13.
引用本文的文献
1
Variant Signaling: Genetic, Hematologic and Immune Implication in Chronic Myeloproliferative Neoplasms.变异信号：慢性骨髓增殖性肿瘤的遗传、血液学和免疫学意义。
Biomolecules. 2022 Feb 11;12(2):291. doi: 10.3390/biom12020291.
本文引用的文献
1
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.阿伯尔·D·A、奥拉齐·A、哈塞尔简·R等。《世界卫生组织髓系肿瘤和急性白血病分类（2016年修订版）》。《血液》。2016年；127(20):2391 - 2405。
Blood. 2016 Jul 21;128(3):462-463. doi: 10.1182/blood-2016-06-721662.
2
ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.ASXL1 和 SETBP1 基因突变及其对慢性粒单核细胞白血病的预后贡献：来自 466 例患者的两项中心研究。
Leukemia. 2014 Nov;28(11):2206-12. doi: 10.1038/leu.2014.125. Epub 2014 Apr 3.
3
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value.骨髓增殖性肿瘤中钙网蛋白突变特异性免疫染色：发病机制见解及诊断价值
Leukemia. 2014 Sep;28(9):1811-8. doi: 10.1038/leu.2014.100. Epub 2014 Mar 12.
4
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.CALR 突变与 JAK2 突变、MPL 突变或三阴性骨髓纤维化的临床、细胞遗传学和分子比较。
Leukemia. 2014 Jul;28(7):1472-7. doi: 10.1038/leu.2014.3. Epub 2014 Jan 9.
5
Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients.原发性骨髓纤维化中 2 年死亡率大于 80%的预测因素：梅奥诊所对 884 例核型注释患者的研究。
Blood. 2011 Oct 27;118(17):4595-8. doi: 10.1182/blood-2011-08-371096. Epub 2011 Aug 31.
6
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.DIPSS plus：一种改良的原发性骨髓纤维化动态国际预后评分系统，纳入了核型、血小板计数和输血状态的预后信息。
J Clin Oncol. 2011 Feb 1;29(4):392-7. doi: 10.1200/JCO.2010.32.2446. Epub 2010 Dec 13.
7
Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis.动态国际预后评分系统（DIPSS）可预测原发性骨髓纤维化进展为急性髓系白血病的情况。
Blood. 2010 Oct 14;116(15):2857-8. doi: 10.1182/blood-2010-06-293415.
8
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.骨髓增殖性肿瘤中的新突变及其功能和临床相关性：JAK2、MPL、TET2、ASXL1、CBL、IDH 和 IKZF1。
Leukemia. 2010 Jun;24(6):1128-38. doi: 10.1038/leu.2010.69. Epub 2010 Apr 29.
9
Cytogenetic Guidelines and Quality Assurance: a common European framework for quality assessment for constitutional and acquired cytogenetic investigations.
Eur J Hum Genet. 2007 May;15(5):525-7. doi: 10.1038/sj.ejhg.5201809. Epub 2007 Mar 14.
10
Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes.关于急性白血病、慢性淋巴细胞白血病、慢性髓细胞白血病、慢性骨髓增殖性疾病和骨髓增生异常综合征细胞遗传学分析标准化方案的建议。
Genes Chromosomes Cancer. 2007 May;46(5):494-9. doi: 10.1002/gcc.20433.
Zotero 插件